ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: Business News
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Digital health company, ResApp Health (RAP) has successfully completed functional testing of handheld and wearable devices
  • The prototypes were given to U.K. based medical device companies, Avanti Med and OSI Electronics for functional testing
  • The Andriod-based, durable handheld device is a low-cost option for using ResApp’s respiratory disease diagnostic apps
  • The wearable devices monitor patients with chronic diseases for up to three days
  • ResApp is up 2.08 per cent on the market today, selling shares for 24¢ apiece

Digital health company, ResApp Health (RAP) has successfully completed functional testing of handheld and wearable devices.

The prototypes were given to U.K. based medical device companies, Avanti Med and OSI Electronics for functional testing.

The Andriod-based, durable handheld device is a low-cost option for using ResApp’s respiratory disease diagnostic apps.

According to the company, the device has a high-resolution touchscreen, a high-quality microphone and can last up to two days without being charged.

The wearable monitor is an easily worn unobtrusive platform which monitors patients with chronic diseases for up to three days.

Chronic diseases include chronic obstructive pulmonary disease (group of lung diseases) and asthma.

CEO Tony Keating is pleased with the performance of the first functional prototypes which were delivered by Avanti and OSI on schedule.

“Complementing our ability to deploy ResAppDx on smartphones, this new handheld device will provide customers with a ruggedized option for in-person clinical environments that demand specific features,” Tony said.

“Looking forward, the wearable monitor provides a unique platform for commercialising new products aimed at assessing and predicting respiratory disease progression,” he added.

Further clinical, electrical and usability evaluation is now underway, with CE Mark approval targeted for the first half of the 2020 calendar year.

ResApp is up 2.08 per cent on the market this morning, selling shares for 24¢ apiece at 11:41 am AEDT.

RAP by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…